- Home
- TVA vs TNGX Comparison
TVA vs TNGX Comparison
Compare TVA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVA
- TNGX
- Stock Information
- Founded
- TVA 2024
- TNGX 2014
- Country
- TVA United States
- TNGX United States
- Employees
- TVA N/A
- TNGX N/A
- Industry
- TVA
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TVA
- TNGX Health Care
- Exchange
- TVA Nasdaq
- TNGX Nasdaq
- Market Cap
- TVA 303.4M
- TNGX 351.2M
- IPO Year
- TVA 2025
- TNGX N/A
- Fundamental
- Price
- TVA $10.07
- TNGX $4.97
- Analyst Decision
- TVA
- TNGX Strong Buy
- Analyst Count
- TVA 0
- TNGX 6
- Target Price
- TVA N/A
- TNGX $12.20
- AVG Volume (30 Days)
- TVA 4.0K
- TNGX 3.9M
- Earning Date
- TVA 01-01-0001
- TNGX 08-06-2025
- Dividend Yield
- TVA N/A
- TNGX N/A
- EPS Growth
- TVA N/A
- TNGX N/A
- EPS
- TVA N/A
- TNGX N/A
- Revenue
- TVA N/A
- TNGX $40,990,000.00
- Revenue This Year
- TVA N/A
- TNGX N/A
- Revenue Next Year
- TVA N/A
- TNGX N/A
- P/E Ratio
- TVA N/A
- TNGX N/A
- Revenue Growth
- TVA N/A
- TNGX 10.09
- 52 Week Low
- TVA $9.99
- TNGX $1.03
- 52 Week High
- TVA $10.25
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- TVA N/A
- TNGX 70.69
- Support Level
- TVA N/A
- TNGX $4.70
- Resistance Level
- TVA N/A
- TNGX $5.63
- Average True Range (ATR)
- TVA 0.00
- TNGX 0.60
- MACD
- TVA 0.00
- TNGX 0.03
- Stochastic Oscillator
- TVA 0.00
- TNGX 73.71
About TVA Texas Ventures Acquisition III Corp Class A Ordinary Share
Texas Ventures Acquisition III Corp is a blank check company.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.